Investment Rating - The investment rating for the company is "Buy" (maintained) [2][15] Core Views - The company has shown strong revenue and profit growth, with Q1 2025 revenue exceeding 1 billion yuan. In 2024, the company achieved a revenue of 3.558 billion yuan, a year-on-year increase of 76.29%, and a net profit attributable to shareholders of 1.430 billion yuan, up 121.97% year-on-year [7][10] - The core product, Fumetnib, has seen robust sales growth, with 2024 sales reaching 3.506 billion yuan, a 77.27% increase year-on-year. Multiple new indications are in the registration clinical phase, which is expected to sustain future growth [8][9] Financial Performance Summary - In Q1 2025, the company reported revenue of 1.098 billion yuan, a year-on-year increase of 47.86% and a quarter-on-quarter increase of 7.22%. The net profit attributable to shareholders was 410 million yuan, up 34.13% year-on-year and 11.88% quarter-on-quarter [7] - The company has revised its profit forecasts for 2025-2026 and added a new forecast for 2027, expecting net profits of 1.843 billion yuan, 2.152 billion yuan, and 2.389 billion yuan for 2025, 2026, and 2027 respectively [7] Product Development and Pipeline - Fumetnib's clinical trials for new indications are progressing well, with approvals for several trials expected to enhance the product's market potential. The NDA for a new indication is anticipated to be submitted in 2025, with approval expected in early 2026 [8][9] - The company is also advancing multiple new products, including Goleirese for KRAS G12C mutation in non-small cell lung cancer, which is expected to receive approval soon [9]

医药生物行业资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002365 | 永安药业 | -4.28 | 40.91 | -13714.20 | | 002693 | 双成药业 | -9.97 | 18.88 | -13065.36 | | 600196 | 复星医药 | -0.25 | 0.82 | -8302.56 | | 003020 | 立方制药 | -10.00 | 17.63 | -8292.64 | | 603205 | 健尔康 | -7.02 | 46.99 | -7465.10 | | 002422 | 科伦药业 | -6.60 | 2.41 | -7319.24 | | 002044 | 美年健康 | -1.92 | 3.40 | -7167.05 | | 688578 | 艾力斯 | -3.48 | 1.26 | -6411.86 | | 600216 | 浙江医药 | -1.30 | 3.42 | -6123.73 | | 300401 | 花园生物 | -4 ...

Group 1 - The Hong Kong innovative drug sector has rebounded rapidly due to a favorable external environment, with the China Securities Hong Kong Innovative Drug Index (931787) experiencing a significant recovery since its low on April 9, 2023 [1][3] - As of April 25, 2023, the index reached a peak of 979.92 points, showing a maximum cumulative increase of 37.43% from its previous low [1] - The overall increase in the Hong Kong innovative drug sector has outperformed the Hang Seng Technology Index, which has only seen a year-to-date increase of 12.48% compared to the innovative drug index's 31.03% [3] Group 2 - Recent data indicates a collective performance improvement among Hong Kong innovative drug companies, significantly exceeding market expectations [4] - In 2024, 10 out of 12 Hong Kong innovative drug companies with a market capitalization over 10 billion HKD reported positive revenue growth, with 8 companies also showing positive profit growth [4] - The company with the highest revenue growth is CloudTop New Drug-B (01952), with a revenue growth rate of 341.8%, while Innovent Biologics (01801) reported a net profit growth of 91.8% [4] Group 3 - The trend of "going global" has become a key topic, with Chinese pharmaceutical companies achieving significant growth in overseas licensing transactions [6][8] - The total transaction amount for licensing-out by Chinese pharmaceutical companies reached a historical high of 51.9 billion USD in 2024, indicating a strong global competitiveness in innovative drug development [6] - The NewCo model has emerged as a favorable strategy for domestic biotech companies, allowing for cash flow support and risk sharing in international collaborations [8] Group 4 - New industry trends in pharmaceuticals, such as weight-loss drugs, dual-antibody drugs, ADC drugs, and innovative medical devices, are expected to create new investment opportunities [9] - The Chinese government is increasing support for innovative drug exports, as evidenced by recent policies aimed at facilitating the import of research materials for biopharmaceutical companies [9] - Despite market fluctuations due to trade tensions, the pharmaceutical sector remains relatively insulated, presenting a favorable opportunity for large-scale investments [9] Group 5 - The Hong Kong innovative drug sector is poised for a valuation recovery, with significant inflows of capital from southbound investors since the beginning of the year [11] - As of April 24, 2023, net capital inflows from A-share investors into Hong Kong stocks reached 611.1 billion HKD, with healthcare becoming the second most net inflow sector [11] - The current price-to-earnings ratio (TTM) for the pharmaceutical and biotechnology sector is 27.1, indicating that the sector is undervalued compared to other growth sectors [12][13]

AI基金东吴医疗服务股票A（013940）披露2025年一季报，第一季度基金利润719.02万元，加权平均基金份额本期利润0.0918元。报告期内，基金净值增长 率为18.83%，截至一季度末，基金规模为4473.8万元。 该基金属于标准股票型基金，长期投资于医药医疗股票。截至4月23日，单位净值为0.583元。基金经理是毛可君，目前管理3只基金。其中，截至4月23日， 东吴医疗服务股票A近一年复权单位净值增长率最高，达17.37%；东吴双三角股票A最低，为-8.68%。 基金管理人在一季报中表示，展望后市，短期来看，国际贸易博弈对市场或有较大冲击，避险情绪或阶段性主导，但中长期看我们依然相对看好我国创新药 为代表的的医药产业发展趋势。 截至4月23日，东吴医疗服务股票A近三个月复权单位净值增长率为17.18%，位于同类可比基金19/54；近半年复权单位净值增长率为8.09%，位于同类可比 基金12/54；近一年复权单位净值增长率为17.36%，位于同类可比基金11/54；近三年复权单位净值增长率为-26.68%，位于同类可比基金36/46。 通过所选区间该基金净值增长率分位图，可以观察该基金与同类基金业绩比 ...

简历显示，杨建楠女士:中国国籍,硕士研究生,历任上海天昊生物科技储备干部,长江证券分析师,建信资 管研究员等职务。现任上银基金基金经理。2022年2月25日起任上银医疗健康混合型证券投资基金基金 经理。 近期份额规模变动情况： 日期期间申购（亿份）期间赎回（亿份）期末总份额（亿份）期末净资产（亿元）净资产变动率2025- 03-310.000.000.020.02-2.54%2024-12-310.000.020.020.02-47.96%2024-09-300.000.020.040.04-27.77%2024- 06-300.290.350.060.06-49.10% 数据显示，该基金近3个月收益率16.91%，近一年收益率6.37%，成立以来收益率为-35.85%。其股票持 仓前十分别为：科伦博泰生物-B、恒瑞医药、科伦药业、信立泰、惠泰医疗、益方生物、海思科、艾力 斯、泽璟制药、百济神州，前十持仓占比合计42.32%。 天眼查商业履历信息显示，上银基金管理有限公司成立于2013年8月，位于上海市，是一家以从事资本 市场服务为主的企业。注册资本30000万人民币，法定代表人为武俊。 来源：金融界 截至2 ...

Core Insights - The company, Shanghai Ailis Pharmaceutical Technology Co., Ltd., reported a significant increase in revenue and net profit for the year 2024, driven by the inclusion of its core product, Furmetin, in the national medical insurance directory [1][3] - The company achieved an operating income of 3.56 billion yuan, a year-on-year increase of 76.29%, and a net profit attributable to shareholders of 1.43 billion yuan, up 121.97% [1] - In the first quarter of 2025, revenue continued to grow, reaching 1.098 billion yuan, a 47.86% increase year-on-year, with net profit rising 34.13% to 410 million yuan [1] Revenue Growth - The core product, Furmetin, has seen steady sales growth since its launch in March 2021, with revenues of 791 million yuan and 2.018 billion yuan in 2022 and 2023, respectively, reflecting year-on-year growth rates of 49.22% and 155.14% [3] - The inclusion of Furmetin in the national medical insurance reimbursement list for both second-line and first-line treatment indications has significantly improved patient access to the medication, supporting sales growth [3] Cost Control and Efficiency - The company implemented various cost control and efficiency measures, which contributed to the substantial increase in net profit [1] R&D Investment - In 2024, the company increased its R&D investment to 482 million yuan, a 53.81% rise compared to the previous year, focusing on self-developed projects and product introductions [5] - The company has been actively expanding its product pipeline in the oncology field through collaborations, including a recent agreement with Gakos for exclusive rights to develop certain inhibitors [5] Commercialization and Production Capacity - The company has built a robust marketing team of over 1,200 personnel and established a nationwide sales network to support the growing demand for Furmetin [4] - To meet the increasing market demand, the company is accelerating the construction of a new production line with an annual capacity of 150 million tablets of Furmetin [4] Dividend Policy - The company plans to distribute a cash dividend of 4 yuan per 10 shares for the 2024 fiscal year and may consider an additional mid-term dividend in 2025 if profitability conditions are met [5]

扈世民｜中信证券 物流和出行服务首席分析师 S1010519040004 物流｜关税影响探讨（二）：优选内需政策受益的航空、物流和集运龙头 应对外部冲击，政策层近期高度重视"做大做强国内大循环"，采取以旧换新补贴扩 容、特定群体补贴、类"消费券"政策等政策组合提振内需，关注受益内需政策加码的 航空、物流和区域集运龙头。1）航空：面对显著上升的采购成本，我们预计国内各 航司将暂停波音飞机的引进计划，假设从4月9日起国内停止引进波音飞机但保持退出 计 划 ， 则 我 们 测 算 2025/2026 年 三 大 航 的 机 队 增 速 或 降 低 1.5pcts/2.1pcts 至 2.9%/2.9%。若假设延迟波音的退出计划叠加航材采购成本上升，我们预计2025年国 内三大航飞机引进增速或降至1%~2%。关税反制进一步限制航空业供给，票价拐点渐 近，国际油价下跌释放利润空间，关注五一前航空布局机会。2）物流：以旧换新国 补扩容及潜在的消费刺激政策有望传导至需求端，选取品类相关度高的顺周期龙头。 3）区域集运：复盘历史，积极的财政政策有望推动大宗商品需求的修复，2024年内 贸行业CR3接近80%，预计需求变化将传 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥1,098,374,566.26, representing a 47.86% increase compared to ¥742,835,715.09 in the same period last year[4] - Net profit attributable to shareholders was ¥410,497,438.67, a 34.13% increase from ¥306,052,559.16 year-on-year[4] - Basic and diluted earnings per share increased to ¥0.91, reflecting a growth of 33.82% compared to ¥0.68 in the prior year[4] - Operating profit for Q1 2025 was RMB 477,078,629.83, compared to RMB 313,917,428.44 in Q1 2024, reflecting a 52.0% increase[21] - Total comprehensive income for Q1 2025 was RMB 346,738,605.88, slightly up from RMB 320,044,154.27 in Q1 2024[22] Research and Development - R&D investment totaled ¥112,129,230.35, up 74.86% from ¥64,126,011.92 in the previous year, accounting for 10.21% of revenue[4] - The company experienced a 43.08% increase in R&D expenses, driven by new clinical projects for Vomeprazole[7] - Research and development expenses increased to RMB 91,754,053.37 in Q1 2025, up 43.3% from RMB 64,126,011.92 in Q1 2024[21] - The company is advancing its clinical research with a newly approved Phase III trial for Furmetin, targeting non-small cell lung cancer patients with non-classical EGFR mutations[14] - The company is committed to developing innovative drugs to meet unmet clinical needs, focusing on First-in-class and Best-in-class therapies[14] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,234,673,159.21, a 5.38% increase from ¥5,916,131,448.10 at the end of the previous year[5] - Total assets as of March 31, 2025, amounted to RMB 6.235 billion, an increase from RMB 5.916 billion at the end of 2024[19] - The total liabilities decreased to RMB 597.48 million from RMB 633.32 million in the previous period[19] - The company’s retained earnings increased to RMB 1.621 billion, up from RMB 1.245 billion at the end of 2024[19] Cash Flow - The net cash flow from operating activities was ¥392,806,950.89, a 7.54% increase from ¥365,255,516.58 in the previous year[4] - Cash flow from operating activities for Q1 2025 was RMB 392,806,950.89, compared to RMB 365,255,516.58 in Q1 2024, indicating a positive trend[24] - The company reported a net cash outflow from investing activities of RMB -581,527,811.19 in Q1 2025, compared to a net inflow of RMB 468,725,625.83 in Q1 2024[24] - The company's cash and cash equivalents stood at RMB 588.61 million, slightly up from RMB 586.99 million at the end of the previous year[17] - Cash and cash equivalents at the end of Q1 2025 were RMB 333,136,530.30, down from RMB 1,917,563,295.01 at the end of Q1 2024[26] Marketing and Sales - The company reported a significant increase in sales expenses by 44.65% due to an expanded marketing team and promotional activities for its product, Vomeprazole[7] - The core product, Furmetin (甲磺酸伏美替尼片), saw continuous sales growth, benefiting an expanding patient population in China[13] - The marketing team is actively promoting the RET inhibitor Pralsetinib (普吉华○R), leveraging synergies from Furmetin's market development[13] - Total operating costs for Q1 2025 were RMB 641,306,439.50, an increase of 47.8% from RMB 433,988,956.35 in Q1 2024[21] Government Support - The company received government subsidies amounting to ¥2,294,972.60, contributing to a 165.26% increase in other income[6]

Financial Performance - The company achieved total revenue of CNY 3,557,930,155.88 in 2024, representing a year-on-year growth of 76.29%[27]. - Net profit attributable to shareholders reached CNY 1,429,847,078.92, an increase of 121.97% compared to the previous year[26]. - The basic earnings per share rose to CNY 3.18, reflecting a significant increase of 122.38% year-on-year[25]. - The weighted average return on equity improved to 29.26%, up by 11.29 percentage points from the previous year[25]. - Research and development investment amounted to CNY 481,531,337.51, increasing by 53.81% year-on-year, but the ratio to revenue decreased to 13.53%[28]. - The company implemented cost control measures, leading to a substantial increase in net profit despite rising revenues[27]. - Total assets grew by 35.18% year-on-year, reaching CNY 5,916,131,448.10 at the end of 2024[26]. - The net assets attributable to shareholders increased by 32.66% to CNY 5,282,813,244.35[26]. - The company maintained a strong cash flow from operating activities, with a net cash flow of CNY 1,566,013,461.28, up 132.12% year-on-year[26]. Dividend Distribution - The proposed cash dividend for the 2024 fiscal year is 292,500,000.00 yuan (including tax), which accounts for 20.46% of the net profit attributable to shareholders of the listed company[5]. - The company plans to distribute a cash dividend of 4.0 yuan (including tax) for every 10 shares, totaling 180,000,000.00 yuan (including tax) based on a total share capital of 450,000,000 shares as of December 31, 2024[4]. - The interim cash dividend for the first half of 2024 is set at 2.50 yuan (including tax) for every 10 shares, amounting to 112,500,000.00 yuan (including tax)[4]. - The board of directors has approved the profit distribution plan, pending approval from the 2024 annual general meeting[4]. Research and Development - The company is focused on developing new drugs for the treatment of non-small cell lung cancer, specifically targeting EGFR mutations[15]. - The company aims to enhance its research capabilities by collaborating with Contract Research Organizations (CROs) for drug development[14]. - The company is committed to achieving a Disease Control Rate (DCR) of over 60% in its clinical trials for new oncology drugs[14]. - The median Progression Free Survival (mPFS) is targeted to exceed 12 months in ongoing clinical studies[14]. - The company plans to submit Investigational New Drug (IND) applications for its leading candidates in the upcoming quarters[14]. - The company has established a comprehensive clinical trial program, including Phase I, II, and III trials, to evaluate the drug's pharmacokinetics and therapeutic effects[15]. - The company is actively conducting clinical trials to expand fumetinib's indications, including first-line and second-line treatments for various mutations[67]. - The company has developed two core technologies: drug molecular design and discovery technology, and metabolism-based drug design and optimization technology[99]. - The company has established a complete new drug R&D system over more than 20 years, focusing on innovative drug development as its core strategy[99]. Product Development and Pipeline - The company reported a new small molecule targeted anti-tumor drug, Fumetinib, which is primarily used for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutations[13]. - The drug has received approval from the National Pharmacopoeia Commission under the generic name Fumetinib tablets[13]. - The company is exploring strategic partnerships and potential acquisitions to bolster its pipeline and market reach[14]. - The company is actively developing AST2303 for treating EGFR C797S mutation advanced NSCLC, with clinical trial approval received in September 2024, currently in Phase I trials[40]. - The company signed a licensing agreement for KRAS G12C inhibitor Goretinib and SHP2 inhibitor AST24082, expanding its oncology pipeline to include treatments for lung, pancreatic, and colorectal cancers[45][46]. - The company is currently conducting a Phase III clinical trial for Furmonertinib in treating EGFR-sensitive non-squamous NSCLC patients with brain metastases, which received IND approval in July 2024[60]. - The company aims to continuously expand the clinical applications of its core product, Furmetinib, targeting various NSCLC indications, including adjuvant therapy and specific mutations[185]. Market and Competitive Landscape - The global oncology drug market size increased from $143.5 billion in 2019 to $228.9 billion in 2023, with a CAGR of 12.4%[85]. - The Chinese oncology drug market grew from RMB 182.7 billion in 2019 to RMB 241.6 billion in 2023, with a CAGR of 7.2%[85]. - The company faces single product dependency risk as Fumetinib will continue to be the main revenue contributor in the near future[121]. - The company is exposed to market competition risks with existing similar drugs already approved and others in various clinical trial stages[122]. - The company is at risk of future price declines for its products due to the competitive landscape and government-led centralized procurement policies[125]. Governance and Compliance - The company has improved its governance mechanisms and compliance management systems, achieving an "A" rating in information disclosure evaluation by the Shanghai Stock Exchange for the 2023-2024 period[49]. - The company is committed to improving its governance structure and internal management systems to ensure compliance with legal regulations and enhance operational efficiency[189]. - The board includes independent directors with extensive experience in finance, law, and academia, contributing to governance and oversight[200]. - The company is committed to maintaining transparency in its financial reporting and governance practices[200]. Talent and Workforce Development - The company is enhancing its talent acquisition and training systems, focusing on new drug development and clinical marketing to build a diverse and experienced team[48]. - The company emphasizes talent development, planning to strengthen its workforce by attracting various professionals and enhancing training systems to improve overall employee skills[188]. - The management team has extensive experience in the pharmaceutical industry, ensuring effective operations in new product development and quality assurance[117].

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 3.1800 | 1.4300 | 122.38 | 0.2900 | | 每股净资产（元） | 11.74 | 8.85 | 32.66 | 7.08 | | 每股公积金(元) | 7.23 | 7.05 | 2.55 | 6.89 | | 每股未分配利润(元) | 2.77 | 0.51 | 443.14 | -0.84 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 35.58 | 20.18 | 76.31 | 7.91 | | 净利润(亿元) | 14.3 | 6.44 | 122.05 | 1.31 | | 净资产收益率(%) | 29.26 | 17.97 | 62.83 | 4.24 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 27506.31万股，累计占流通股比： 61 ...